Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, announces it has raised approximately £24,000 (before expenses) by way of a placing of 53,333 New Ordinary Shares of 0.1p each (‘Placing Shares’) at a price of 45p (the ‘Placing’) with Wilton International Marketing Limited.
Admission and commencement of dealings in the New Ordinary Shares to be issued under the Placing are expected to take place at 8.00 a.m. on 11 May 2010. There will be a total of 15,926,659 Ordinary Shares in issue following Admission of the Placing Shares.
The Directors of the issuer accept responsibility for this announcement.
For further information contact:
David Evans - Scancell Holdings Plc - +44 (0) 774 008 4452
Kirsty Corcoran / John Bick - Hansard Communications - +44 (0)207 245 1100
Ross Andrews / Tom Rowley - Zeus Capital - +44 (0)161 831 1512
Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is expected to enter clinical trials in 2010.
Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.
An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.
The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.
A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D
Tue, 20 Aug 2019 06:05:00
Mon, 19 Aug 2019 11:32:00
Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date
Mon, 19 Aug 2019 06:46:00